The Potential Role of Firboblast Activation Protein as a Natural Killer Cell Immune Checkpoint in Pancreatic Cancer
成纤维细胞激活蛋白作为自然杀伤细胞免疫检查点在胰腺癌中的潜在作用
基本信息
- 批准号:10600089
- 负责人:
- 金额:$ 2.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:Activated Natural Killer CellAttenuatedBiologicalBiologyCell CommunicationCell LineCell Surface ReceptorsCellsCicatrixClinicalClinical TrialsCoculture TechniquesDataDesmoplasticDipeptidyl PeptidasesDiseaseEndopeptidasesExposure toExtracellular MatrixFailureFibrosisFlow CytometryGoalsHumanImmuneImmune responseImmunosuppressionImmunotherapyIn VitroInfiltrationInvadedKnock-outKnowledgeLesionLifeMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMembraneModelingMonitorMusNK Cell ActivationNatural Killer CellsOutcomePancreasPancreatic Ductal AdenocarcinomaPatternPhenotypePopulationProtein InhibitionPublic DomainsRadiation therapyReceptor CellRoleSamplingSerine ProteaseSignaling MoleculeSurvival RateSystemTestingThickTimeTissuesTumor ImmunityTumor PromotionWorkangiogenesisanti-PD1 therapyanti-canceranti-tumor immune responseantitumor effectcell typechemotherapyclinical applicationclinically relevantcytokinecytotoxicityfibroblast activation protein alphafibroblast-activating factorhuman dataimaging systemimmune cell checkpointsimmune clearanceimmunogenicimprovedin vitro activityin vivoliquid crystal polymerlive cell imagingmigrationmouse modelnano-stringnovelnovel strategiesoverexpressionpancreatic cancer patientspancreatic ductal adenocarcinoma modelpancreatic neoplasmpancreatic stellate cellpathology imagingpharmacologicprotein activationprotein biomarkersprotein expressionprotein functionresponsetherapeutic targettooltumortumor growthtumor-immune system interactions
项目摘要
PROJECT SUMMARY
Immunotherapy has been largely ineffective in pancreatic cancer, partially due to the surrounding dense stromal
fibrosis which creates an immunosuppressive microenvironment. The main cellular component of this fibrosis,
pancreatic stellate cells (PSCs), are marked by elevated expression of fibroblast activation protein (FAP). FAP
is a type II transmembrane serine protease that is minimally expressed in normal pancreas, however, in
pancreatic cancer FAP is overexpressed in 90% of lesions and is associated with worse clinical outcomes. Here
we use a novel in vitro co-culturing system that utilizes primary donor-derived PSCs and a human natural killer
(NK) cell line, NK92, to assess the relationship between PSCs and NK cells. We tested the ability of NK cells to
kill PSCs and monitored for FAP expression and markers of activation. We also assessed the effect of FAP
inhibition on NK cell activity in vitro and pancreatic tumor clearance in vivo. We found that NK cells are activated
by and kill PSCs, potentially via NK cell surface receptor NKG2D recognition of MICA/B on PSCs. Upon direct
contact with PSCs, PSCs downregulate FAP, however, NK cells upregulate FAP. This is the first-time NK cells
have been shown to produce FAP and that induction of FAP is mediated by cell-to-cell contact. Furthermore,
FAP expression by NK cells is associated with an inactivate phenotype. FAP inhibition enhanced NK killing of
PSCs in vitro and enhanced pancreatic tumor clearance in vivo. The anti-tumor activity of FAP inhibition was
enhanced by addition of anti-PD-1 therapy. Based on these findings, I hypothesize that FAP functions as an NK
cell immune checkpoint. FAP is expressed in NK cells after activation to attenuate cytotoxicity and can be
inhibited to enhance anti-tumor immunity. To test this hypothesis, I aim to determine mechanisms of FAP
induction in NK cells (Aim 1), assess the clinical relevance of these findings (Aim 1A and 1D) and manipulate
FAP activity to enhance in vitro and in vivo anti-tumor immune responses (Aim 2). Successful completion of
these aims will identify factors that regulate FAP expression and further our understanding of how FAP regulates
the immune response. These findings will fill the gap in knowledge surrounding regulators of FAP expression
and provide new approaches to enhance anti-tumor immune activity.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Allison O'Connell其他文献
Allison O'Connell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Allison O'Connell', 18)}}的其他基金
The Potential Role of Firboblast Activation Protein as a Natural Killer Cell Immune Checkpoint in Pancreatic Cancer
成纤维细胞激活蛋白作为自然杀伤细胞免疫检查点在胰腺癌中的潜在作用
- 批准号:
10373963 - 财政年份:2019
- 资助金额:
$ 2.77万 - 项目类别:
The Potential Role of Firboblast Activation Protein as a Natural Killer Cell Immune Checkpoint in Pancreatic Cancer
成纤维细胞激活蛋白作为自然杀伤细胞免疫检查点在胰腺癌中的潜在作用
- 批准号:
9921199 - 财政年份:2019
- 资助金额:
$ 2.77万 - 项目类别:
The Potential Role of Firboblast Activation Protein as a Natural Killer Cell Immune Checkpoint in Pancreatic Cancer
成纤维细胞激活蛋白作为自然杀伤细胞免疫检查点在胰腺癌中的潜在作用
- 批准号:
9758543 - 财政年份:2019
- 资助金额:
$ 2.77万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 2.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 2.77万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 2.77万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 2.77万 - 项目类别:
Idea to Innovation